Schrödinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Schrödinger, Inc. (NASDAQ:SDGR) have been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $33.00.

A number of analysts have recently commented on SDGR shares. Piper Sandler cut their target price on Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. KeyCorp lifted their price target on Schrödinger from $30.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th.

Insider Transactions at Schrödinger

In related news, insider Karen Akinsanya sold 16,723 shares of Schrödinger stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $25.09, for a total value of $419,580.07. Following the sale, the insider now directly owns 15,625 shares in the company, valued at $392,031.25. The trade was a 51.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Geoffrey Craig Porges sold 5,491 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the sale, the chief financial officer now owns 27,544 shares in the company, valued at $599,357.44. The trade was a 16.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Schrödinger

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Hong Kong Ltd acquired a new position in Schrödinger during the fourth quarter worth $27,000. Paradigm Asset Management Co. LLC acquired a new position in shares of Schrödinger during the 4th quarter worth $50,000. GAMMA Investing LLC raised its stake in shares of Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after buying an additional 1,305 shares during the last quarter. KBC Group NV boosted its position in shares of Schrödinger by 73.9% in the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock worth $84,000 after buying an additional 1,853 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in Schrödinger in the 4th quarter valued at about $199,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Schrödinger Price Performance

Shares of NASDAQ SDGR opened at $26.45 on Monday. The business has a 50-day moving average of $22.14 and a two-hundred day moving average of $21.28. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -11.30 and a beta of 1.77. Schrödinger has a 1 year low of $16.60 and a 1 year high of $28.47.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The business had revenue of $88.32 million during the quarter, compared to analyst estimates of $83.20 million. As a group, equities research analysts expect that Schrödinger will post -2.37 earnings per share for the current year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.